AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00143663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
Trial: NCT00004873
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01921751
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
Trial: NCT01785459
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Intravenous injection of Prochlorperazine
Trial: NCT01075412
Drug: [F18]Fluorothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT PET scan 5 mCi (+/- 10%)
Trial: NCT00552175
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken orally every day
Trial: NCT01496131
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
Trial: NCT00000580
Drug: immunoglobulins, intravenous
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04018339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing an inert placebo
Trial: NCT02153528
Drug: double rimfampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
Trial: NCT03548675
Drug: TCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
Trial: NCT02153528
Drug: Standard TB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Trial: NCT02431936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill made to look identical to Prazosin intervention.
Trial: NCT01833611
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo qd
Trial: NCT01784770
Drug: Azithromycin IV
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Trial: NCT01425827
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar looking tablets to the active agent for 16 weeks
Trial: NCT00658762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, oral, BID, 8 weeks, with 2 week taper
Trial: NCT01229618
Drug: Hyperpolarized Pyruvate (13C) injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Trial: NCT01286090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet taken orally 4 times a day for up to 8 weeks.
Trial: NCT00770718
Drug: Recombinant Activated Factor VII (rFVIIa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
Trial: NCT04489745
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03225456
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal placebo
Trial: NCT04239833
Drug: Placebo SH-1028 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT00018733
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01298752
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
Trial: NCT03459807
Drug: Anti-Hypertensive medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of standard Anti-Hypertensive medications
Trial: NCT00449592
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Zincol 1 Tab TID from day -6/-7 until discharge
Trial: NCT00449592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo 1 Tab TID from day -6/-7 until discharge
Trial: NCT00359281
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
Trial: NCT00448903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0,9%
Trial: NCT01746485
Drug: UT-15C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01891500
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
Trial: NCT01664559
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 30mg intramuscular injection, 1cc volume
Trial: NCT01664559
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
Trial: NCT00220415
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03655535
Drug: BTI320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-systemic galactomannan complex polysaccharide
Trial: NCT03211403
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 or placebo once daily for a week
Trial: NCT01448902
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 200mg bid for 8 days
Trial: NCT01448902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid for 8 days
Trial: NCT01734265
Drug: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01734265
Drug: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534688
Drug: LNG-IUS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00617500
Drug: Hormones
RxNorm normalized name: Other hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 1 mg and a drospirenone 2mg/day (3 months)
Trial: NCT04021589
Drug: Weileshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a probiotics products which help to rebuild homeostasis of gut microbiome
Trial: NCT00950989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Trial: NCT00950989
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
Trial: NCT00803686
Drug: Oral rsCT tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
Trial: NCT00803686
Drug: Oral Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
Trial: NCT04021589
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT00803686
Drug: Oral rsCT tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
Trial: NCT00803686
Drug: Fortical (rsCT) nasal spray
RxNorm normalized name: Fortical Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
Trial: NCT01916408
Drug: Wobenzym plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Trial: NCT01916408
Drug: PL 1
RxNorm normalized name: ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Trial: NCT00091104
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04688775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
Trial: NCT03041025
Drug: GSK2330811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
Trial: NCT03041025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9 percent weight per volume sodium chloride).
Trial: NCT01897844
Drug: ITF2984 (100, 2000, 3000 mcg bid)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01897844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00813592
Drug: SOM230B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
Trial: NCT01225731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration of Placebo
Trial: NCT01759277
Drug: Control: Femoral perineural local anesthetic infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
Trial: NCT01759277
Drug: Experimental: Adductor Canal perineural local anesthetic infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
Trial: NCT02236247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill (identical to ivabradine) will be administered twice daily
Trial: NCT01113424
Drug: Nicorette® (Nicotine Gum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of marketed nicotine gum 2 mg or 4 mg
Trial: NCT01252745
Drug: 10.0 mg of Testosterone, 4.0% TID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252745
Drug: 13.5 mg of Testosterone, 4.5% B.I.D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252745
Drug: 11.25 mg of Testosterone, 4.5% T.I.D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03261310
Drug: Acetaminophen or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.
Trial: NCT01659580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225mg bid
Trial: NCT01840579
Drug: G-CSF (pegfilgrastim) 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a subcutaneous injection on Day 4 of Cycle 1
Trial: NCT04315194
Drug: clarithromycin-naproxen-oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
Trial: NCT01435941
Drug: Non-steroidal anti-inflammatory drug (NSAID)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
Trial: NCT01435941
Drug: Triptan
RxNorm normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
Trial: NCT02329080
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
Trial: NCT02695901
Drug: Nanoparticle solution of M. alternifolia oil (0.3%).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
Trial: NCT02034201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00725881
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
Trial: NCT00239278
Drug: prednisolone, 30 mg once daily and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04742283
Drug: DE-126 Ophthalmic Solution 0.002% QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
Trial: NCT02424097
Drug: 1,100pm F-toothpaste and 0.5%NaF rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)
Trial: NCT02072018
Drug: H-100
RxNorm normalized name: steareth-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
Trial: NCT02072018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
Trial: NCT00708123
Drug: Placebo toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride free toothpaste (0 ppm F)
Trial: NCT03864575
Drug: Celecoxib 400 mg
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg/day in combination with nivolumab fixed dose
Trial: NCT01231594
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT01231594
Drug: Other approved anti-cancer agent
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT03008850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Trial: NCT01012375
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule, oral dose
Trial: NCT01012375
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg capsule, oral dose
Trial: NCT01012375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule, oral dose
Trial: NCT01057407
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01868880
Drug: betablocker titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
Trial: NCT03991143
Drug: ATH3G10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT03991143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT01723059
Drug: Standard Triple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 10 days
Trial: NCT01723059
Drug: Sequential Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total 10 days
Trial: NCT03219580
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
Trial: NCT01422122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one table spoon Syrup per day
Trial: NCT00385502
Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nail lacquer applied daily for 48 weeks
Trial: NCT00272142
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00272142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03159091
Drug: Rengalin
RxNorm normalized name: Sengalia catechu wood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT03159091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT00788372
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
Trial: NCT03790345
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant daily treatment with 200mg of pyridoxine
Trial: NCT02258451
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 6 cycles of saline injection
Trial: NCT01018628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.